Advertisement

Symptoms and Work-Up

  • Jungyo Suh
Chapter

Abstract

The diagnostic process of bladder cancer consists of checking the medical history, urine cytology, cystoscopic exam, and imaging work-up. Cystoscopic exam and urinary cytology played the most important role; however, medical history is also important for diagnosis. Hematuria is the most common symptom of bladder cancer. About 90% of bladder cancer patients present with hematuria at the time of diagnosis, which is either gross or microscopic. Gross hematuria is more strongly correlated with advanced bladder cancer. Some of the lower urinary tract symptoms, such as dysuria, frequency, and urgency, are reported in 20% of bladder cancer patients and possible indicators of carcinoma in situ (CIS).

Keywords

Hematuria Gender difference Asymptomatic microscopic hematuria Lower urinary tract symptoms 

References

  1. 1.
    Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22.  https://doi.org/10.1046/j.1523-5394.2002.106011.x.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, et al. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int. 2016;117:783–6.  https://doi.org/10.1111/bju.13345.CrossRefPubMedGoogle Scholar
  3. 3.
    Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163:524–7.  https://doi.org/10.1016/S0022-5347(05)67916-5.CrossRefPubMedGoogle Scholar
  4. 4.
    Jones R, Latinovic R, Charlton J, Gulliford MC. Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database. BMJ. 2007;334:1040.  https://doi.org/10.1136/bmj.39171.637106.AE.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. Cochrane Database Syst Rev. 2015;1:CD010007.  https://doi.org/10.1002/14651858.CD010007.pub2.CrossRefPubMedGoogle Scholar
  6. 6.
    Bangma CH, Loeb S, Busstra M, Zhu X, El Bouazzaoui S, Refos J, et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur Urol. 2013;64:41–7.  https://doi.org/10.1016/j.eururo.2013.02.036.CrossRefPubMedGoogle Scholar
  7. 7.
    Steiner H, Bergmeister M, Verdorfer I, Granig T, Mikuz G, Bartsch G, et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int. 2008;102:291–6.  https://doi.org/10.1111/j.1464-410X.2008.07596.x.CrossRefPubMedGoogle Scholar
  8. 8.
    Tu WH, Shortliffe LD. Evaluation of asymptomatic, atraumatic hematuria in children and adults. Nat Rev Urol. 2010;7:189–94.  https://doi.org/10.1038/nrurol.2010.27.CrossRefPubMedGoogle Scholar
  9. 9.
    Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, et al. What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urol Oncol Semin Orig Investig. 2014;32:128–34.  https://doi.org/10.1016/j.urolonc.2012.07.001.CrossRefGoogle Scholar
  10. 10.
    Mungan NA, Kiemeney LA, Van Dijck JA, Van Der Poel HG, Witjes JA. Gender differences in stage distribution of bladder cancer. Urology. 2000;55:368–71.  https://doi.org/10.1016/S0090-4295(99)00481-1.CrossRefPubMedGoogle Scholar
  11. 11.
    Garg T, Pinheiro LC, Atoria CL, Donat SM, Weissman JS, Herr HW, et al. Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. J Urol. 2014;192:1072–7.  https://doi.org/10.1016/j.juro.2014.04.101.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115:68–74.  https://doi.org/10.1002/cncr.23986.CrossRefPubMedGoogle Scholar
  13. 13.
    Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188:2473–81.  https://doi.org/10.1016/j.juro.2012.09.078.CrossRefPubMedGoogle Scholar
  14. 14.
    Sharp VJ, Barnes KT, Erickson BA. Assessment of asymptomatic microscopic hematuria in adults. Am Fam Physician. 2013;88:747–54.  https://doi.org/10.1016/S1002-0721(12)60414-1.CrossRefPubMedGoogle Scholar
  15. 15.
    Horie S, Ito S, Okada H, Kikuchi H, Narita I, Nishiyama T, et al. Japanese guidelines of the management of hematuria 2013. Clin Exp Nephrol. 2014;18:679–89.  https://doi.org/10.1007/s10157-014-1001-2.CrossRefPubMedGoogle Scholar
  16. 16.
    Brigden ML, Edgell D, McPherson M, Leadbeater A, Hoag G. High incidence of significant urinary ascorbic acid concentrations in a west coast population--implications for routine urinalysis. Clin Chem. 1992;38:426–31.PubMedGoogle Scholar
  17. 17.
    Rao PK, Gao T, Pohl M, Jones JS. Dipstick pseudohematuria: unnecessary consultation and evaluation. J Urol. 2010;183:560–5.  https://doi.org/10.1016/j.juro.2009.10.049.CrossRefPubMedGoogle Scholar
  18. 18.
    Pow-Sang JM, Seigne JD. Contemporary management of superficial bladder cancer. Cancer Control. 2000;7:335–9.  https://doi.org/10.1177/107327480000700402.CrossRefPubMedGoogle Scholar
  19. 19.
    Tissot WD, Diokno AC, Peters KM. A referral center’s experience with transitional cell carcinoma misdiagnosed as interstitial cystitis. J Urol. 2004;172:478–80.  https://doi.org/10.1097/01.ju.0000132323.89037.73.CrossRefPubMedGoogle Scholar
  20. 20.
    Large MC, Cohn JA, Steinberg GD. Optimal risk-adapted surveillance strategies for NMIBC, including upper tract imaging. Urol Clin North Am. 2013;40:305–15.  https://doi.org/10.1016/j.ucl.2013.01.013.CrossRefPubMedGoogle Scholar
  21. 21.
    Cowan NC. CT urography for hematuria. Nat Rev Urol. 2012;9:218–26.  https://doi.org/10.1038/nrurol.2012.32.CrossRefPubMedGoogle Scholar
  22. 22.
    Jinzaki M, Tanimoto A, Shinmoto H, Horiguchi Y, Sato K, Kuribayashi S, et al. Detection of bladder tumors with dynamic contrast-enhanced MDCT. Am J Roentgenol. 2007;188:913–8.  https://doi.org/10.2214/AJR.06.0511.CrossRefGoogle Scholar
  23. 23.
    Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int. 2017;119:371–80.  https://doi.org/10.1111/bju.13760.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. EAU guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Assoc Urol. 2016. http://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/.

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jungyo Suh
    • 1
  1. 1.Department of UrologySeoul National University HospitalSeoulSouth Korea

Personalised recommendations